New service brings together free and low-cost generic medications, affordable online care visits, an

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises

Cramer recommends buying Chevron (CVX) due to good cash flow and limited downside, and waiting to bu

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the

GoodRx Holdings (NASDAQ:GDRX) raises FY2026 sales outlook from $750.000 million-$780.000 million to

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.07 per share which met the analyst c

GoodRx (NASDAQ:GDRX), the leading platform for prescription savings in the U.S., today announced tha

GoodRx shares rise as Wegovy HD rollout expands self-pay access, with tiered pricing and mixed techn

Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support throu

GoodRx shares rise after expanding Eli Lilly's GLP-1 access; analysts keep Buy rating ahead of M

GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced th

Collaboration expands access to trusted therapies with discounted cash prices for leading brands inc

Wells Fargo analyst Stan Berenshteyn maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight an

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers

Goldman Sachs analyst Eric Sheridan maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lo

Mizuho analyst Steven Valiquette maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lower

Sentiment Change Creates Opportunity

GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed t

Jefferies analyst Glen Santangelo downgrades GoodRx Holdings (NASDAQ:GDRX) from Buy to Hold and l

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers

Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices

Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weig

6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes dou

Barclays analyst Glen Santangelo initiates coverage on GoodRx Holdings (NASDAQ:GDRX) with a Under

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prep

JP Morgan analyst Lisa Gill maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and lowers

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and lowers the

https://x.com/JenniferJJacobs/status/1986518429478568383

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and lowers the

GoodRx Holdings (NASDAQ:GDRX) reported quarterly earnings of $0.08 per share which missed the analys

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to l

The all-in-one solution includes a virtual consultation, clinically proven prescription medication,

https://www.hy-vee.com/corporate/news-events/news-press-releases/hyvee-pharmacy-patients-can-now-pur

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescrip

TrumpRx may expand beyond direct sales by drugmakersPharmacies seek role in TrumpRx for discount vou

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innov

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer disco

Hims & Hers Health shares are trading lower Tuesday after GoodRx announces a collaboration with

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positi

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the compa

GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $